Anatara Lifesciences Ltd (ASX:ANR)
Australia
· Delayed Price · Currency is AUD 0.0050
0.00 (0.00%)
Apr 24, 2025, 3:07 PM AEST
Anatara Lifesciences Company Description
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia.
The company offers Gastrointestinal ReProgramming, a proprietary formulation to address irritable bowel syndrome.
It also provides Detach for the treatment of diarrhea disease in piglets. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Anatara Lifesciences Ltd
| Country | Australia |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | David Brookes |
Contact Details
Address: 81 Flinders Street Adelaide, 5000 Australia | |
| Phone | 61 4 3802 7172 |
| Website | anataralifesciences.com |
Stock Details
| Ticker Symbol | ANR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ANR0 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS | Executive Chairman and MD |
| John Michailidis B.Sc., EMBA, M.A.I.C.D. | Chief Operating Officer and Executive Director |
| Simon Erskine | Chief Development Officer |
| Jonathan Lindh | Company Secretary and Non-Executive Director |
| Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management | Commercial Manager |